Publications in collaboration with researchers from Hospital Universitario La Paz (6)

2014

  1. White fish reduces cardiovascular risk factors in patients with metabolic syndrome: The WISH-CARE study, a multicenter randomized clinical trial

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 24, Núm. 3, pp. 328-335

2013

  1. Pegvisomant and cabergoline combination therapy in acromegaly

    Pituitary, Vol. 16, Núm. 1, pp. 101-108

2010

  1. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154

  2. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229

2009

  1. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radio therapy

    European Journal of Endocrinology, Vol. 160, Núm. 4, pp. 535-542

2006

  1. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial

    Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326